William Blair Forecasts Qiagen's Q2 Earnings (NYSE:QGEN)

Key Points

• William Blair has revised its Q2 2026 earnings forecast for Qiagen, lowering it from $0.63 to $0.62 per share, while projecting Q3 earnings at $0.63 EPS.
• In Q2, Qiagen reported earnings of $0.60 per share, meeting consensus estimates, with revenues of $533.54 million, which exceeded expectations by $9.57 million and represented a 7.7% increase year-over-year.
• Qiagen's stock is currently rated as "Hold" by analysts, with an average price target of $49.69, amid varying outlooks from other firms on the stock's performance.

Qiagen N.V. (NYSE:QGEN - Free Report) - Analysts at William Blair reduced their Q2 2026 earnings estimates for shares of Qiagen in a research note issued to investors on Thursday, August 7th. William Blair analyst A. Brackmann now forecasts that the company will post earnings per share of $0.62 for the quarter, down from their previous estimate of $0.63. The consensus estimate for Qiagen's current full-year earnings is $2.26 per share. William Blair also issued estimates for Qiagen's Q3 2026 earnings at $0.63 EPS.

Qiagen (NYSE:QGEN - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The business had revenue of $533.54 million for the quarter, compared to analysts' expectations of $523.97 million. During the same period in the prior year, the company posted $0.55 EPS. The business's revenue for the quarter was up 7.7% compared to the same quarter last year.

Several other analysts have also recently issued reports on the stock. Barclays initiated coverage on shares of Qiagen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price on the stock. Wall Street Zen cut shares of Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Monday. Robert W. Baird increased their target price on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Bank of America raised their price objective on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. Finally, Cowen restated a "hold" rating on shares of Qiagen in a research report on Thursday. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $49.69.

Qiagen Stock Performance

NYSE QGEN opened at $48.02 on Monday. Qiagen has a 1 year low of $37.63 and a 1 year high of $51.88. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The stock has a market capitalization of $10.67 billion, a PE ratio of 28.37, a P/E/G ratio of 2.45 and a beta of 0.64. The company's 50 day simple moving average is $48.02 and its two-hundred day simple moving average is $43.54.

Hedge Funds Weigh In On Qiagen

Institutional investors and hedge funds have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC bought a new position in shares of Qiagen during the 4th quarter valued at $202,000. Wells Fargo & Company MN grew its holdings in shares of Qiagen by 31.8% during the 4th quarter. Wells Fargo & Company MN now owns 66,779 shares of the company's stock valued at $2,974,000 after purchasing an additional 16,106 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Qiagen by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after purchasing an additional 1,425 shares during the last quarter. LPL Financial LLC grew its holdings in shares of Qiagen by 2.6% during the 4th quarter. LPL Financial LLC now owns 17,240 shares of the company's stock valued at $768,000 after purchasing an additional 432 shares during the last quarter. Finally, Avantax Advisory Services Inc. grew its holdings in shares of Qiagen by 30.2% during the 1st quarter. Avantax Advisory Services Inc. now owns 9,869 shares of the company's stock valued at $396,000 after purchasing an additional 2,290 shares during the last quarter. Institutional investors own 70.00% of the company's stock.

Qiagen Dividend Announcement

The firm also recently announced a dividend, which was paid on Thursday, July 10th. Investors of record on Thursday, July 3rd were issued a dividend of $0.25 per share. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a dividend yield of 52.0%. Qiagen's dividend payout ratio (DPR) is currently 14.79%.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.